The earnings call presented a generally positive outlook with strong financial performance and promising developments in the Breast Health and Diagnostics segments. Despite some challenges in specific markets and product lines, the company's strategic initiatives and successful product launches indicate a solid path toward growth.

Company Guidance

During Hologic's Third Quarter Fiscal 2025 earnings call, the company reported exceeding its guidance with total revenue reaching $1.024 billion, a 0.4% increase year-over-year, surpassing the high end of their guidance by $14 million. The Diagnostics division achieved revenue of $448.9 million, growing 2.9% organically when excluding COVID-related sales, while the Breast Health business, despite a 5.8% decline, showed sequential improvement. The Surgical segment saw a 6.3% increase in revenue, and the Skeletal business grew 62.1% following a resumption in DEXA model shipments. Non-GAAP earnings per share rose by 1.9% to $1.08, slightly above guidance, with a strong operating margin of over 30%. The company anticipates mid-single-digit organic revenue growth into fiscal 2026, bolstered by strengthening in the Breast Health sector and strategic innovations like the Genius AI Detection PRO.

Strong Financial Performance

Hologic delivered revenue and non-GAAP earnings per share that exceeded guidance, with total revenue for the third quarter at $1.024 billion, marking a slight growth of 0.4% and exceeding the high end of guidance by $14 million.

Breast Health Business Improvement

The Breast Health business showed signs of recovery with increased 3D gantry shipments and a positive performance in interventional sales, which grew 6% organically.

Successful Product Launches

The company launched Genius AI Detection PRO, an AI solution for mammogram analysis, and made significant progress with Endomagnetics, which contributed nearly $20 million in revenue.

Diagnostics Growth

Molecular Diagnostics showed global growth of 2.4% or 5.2% excluding COVID-related sales, driven by strong sales of BV, CV/TV assay.

Tariff Mitigation Success

Hologic managed to reduce expected quarterly tariff expenses from $20-25 million to $10-12 million through changes in global supply chain and procurement efforts.

Hologic (HOLX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HOLX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 03, 2025	2025 (Q4)	1.10 / -	1.01	―	―	―
Jul 30, 2025	2025 (Q3)	1.06 / 1.08	1.06	1.89% (+0.02)
May 01, 2025	2025 (Q2)	1.02 / 1.03	1.03	0.00% (0.00)
Feb 05, 2025	2025 (Q1)	1.01 / 1.03	0.98	5.10% (+0.05)	―
Nov 04, 2024	2024 (Q4)	1.01 / 1.01	0.89	13.48% (+0.12)
Jul 29, 2024	2024 (Q3)	1.02 / 1.06	0.93	13.98% (+0.13)
May 02, 2024	2024 (Q2)	0.98 / 1.03	1.06	-2.83% (-0.03)
Feb 01, 2024	2024 (Q1)	0.95 / 0.98	1.07	-8.41% (-0.09)
Nov 09, 2023	2023 (Q4)	0.84 / 0.89	0.82	8.54% (+0.07)
Jul 31, 2023	2023 (Q3)	0.89 / 0.93	0.95	-2.11% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HOLX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$64.98	$66.82	+2.83%
May 01, 2025	$57.28	$54.16	-5.45%
Feb 05, 2025	$72.80	$65.45	-10.10%
Nov 04, 2024	$83.72	$78.80	-5.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.